abrdn Life Sciences Investors (NYSE:HQL) Short Interest Up 70.9% in August

by · The Markets Daily

abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 100,177 shares, a growth of 70.9% from the August 15th total of 58,626 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 160,266 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On abrdn Life Sciences Investors

Several hedge funds have recently made changes to their positions in the business. KPP Advisory Services LLC boosted its stake in shares of abrdn Life Sciences Investors by 2.7% during the 2nd quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock worth $505,000 after acquiring an additional 660 shares in the last quarter. Uhlmann Price Securities LLC lifted its holdings in shares of abrdn Life Sciences Investors by 2.3% during the first quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock valued at $1,267,000 after purchasing an additional 1,719 shares during the last quarter. 180 Wealth Advisors LLC boosted its position in shares of abrdn Life Sciences Investors by 2.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares during the period. NewEdge Advisors LLC boosted its position in shares of abrdn Life Sciences Investors by 17.6% in the 1st quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock valued at $387,000 after purchasing an additional 3,562 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in abrdn Life Sciences Investors by 4.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 91,519 shares of the company’s stock worth $1,489,000 after purchasing an additional 3,666 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Trading Up 1.4%

HQL stock traded up $0.27 during trading hours on Thursday, hitting $19.55. 124,620 shares of the stock traded hands, compared to its average volume of 130,080. The stock has a 50-day simple moving average of $20.39 and a 200 day simple moving average of $18.55. abrdn Life Sciences Investors has a one year low of $14.01 and a one year high of $22.67.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 12.7%. The ex-dividend date of this dividend is Monday, August 24th.

abrdn Life Sciences Investors Company Profile

(Get Free Report)

abrdn Life Sciences Investors (NYSE:HQL) is a non-diversified, closed-end investment company focused on the global life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, healthcare services and other related industries.

The fund may invest in both publicly traded and privately held companies across various stages of development, including businesses developing innovative therapies, diagnostic technologies and other healthcare products.

Featured Articles